1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Angion Biomedica Corp. - Product Pipeline Review - 2015

Angion Biomedica Corp. - Product Pipeline Review - 2015

  • October 2015
  • -
  • Global Markets Direct
  • -
  • 30 pages

Angion Biomedica Corp. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Angion Biomedica Corp. - Product Pipeline Review - 2015’, provides an overview of the Angion Biomedica Corp.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Angion Biomedica Corp.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Angion Biomedica Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Angion Biomedica Corp.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Angion Biomedica Corp.’s pipeline products

Reasons to buy

- Evaluate Angion Biomedica Corp.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Angion Biomedica Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Angion Biomedica Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Angion Biomedica Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Angion Biomedica Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Angion Biomedica Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Angion Biomedica Corp. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Angion Biomedica Corp. Snapshot 5
Angion Biomedica Corp. Overview 5
Key Information 5
Key Facts 5
Angion Biomedica Corp. - Research and Development Overview 6
Key Therapeutic Areas 6
Angion Biomedica Corp. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Angion Biomedica Corp. - Pipeline Products Glance 11
Angion Biomedica Corp. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Angion Biomedica Corp. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Angion Biomedica Corp. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Angion Biomedica Corp. - Drug Profiles 15
BB-3 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
ANG-3070 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
ANG-3279 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
ANG-3281 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
ANG-4011 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Angion Biomedica Corp. - Pipeline Analysis 22
Angion Biomedica Corp. - Pipeline Products by Target 22
Angion Biomedica Corp. - Pipeline Products by Route of Administration 23
Angion Biomedica Corp. - Pipeline Products by Molecule Type 24
Angion Biomedica Corp. - Pipeline Products by Mechanism of Action 25
Angion Biomedica Corp. - Recent Pipeline Updates 26
Angion Biomedica Corp. - Dormant Projects 27
Angion Biomedica Corp. - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 29
Disclaimer 30

List of Tables
Angion Biomedica Corp., Key Information 5
Angion Biomedica Corp., Key Facts 5
Angion Biomedica Corp. - Pipeline by Indication, 2015 7
Angion Biomedica Corp. - Pipeline by Stage of Development, 2015 9
Angion Biomedica Corp. - Monotherapy Products in Pipeline, 2015 10
Angion Biomedica Corp. - Phase III, 2015 11
Angion Biomedica Corp. - Phase II, 2015 12
Angion Biomedica Corp. - Preclinical, 2015 13
Angion Biomedica Corp. - Discovery, 2015 14
Angion Biomedica Corp. - Pipeline by Target, 2015 22
Angion Biomedica Corp. - Pipeline by Route of Administration, 2015 23
Angion Biomedica Corp. - Pipeline by Molecule Type, 2015 24
Angion Biomedica Corp. - Pipeline Products by Mechanism of Action, 2015 25
Angion Biomedica Corp. - Recent Pipeline Updates, 2015 26
Angion Biomedica Corp. - Dormant Developmental Projects,2015 27

List of Figures
Angion Biomedica Corp. - Pipeline by Top 10 Indication, 2015 7
Angion Biomedica Corp. - Pipeline by Stage of Development, 2015 9
Angion Biomedica Corp. - Monotherapy Products in Pipeline, 2015 10
Angion Biomedica Corp. - Pipeline by Top 10 Target, 2015 22
Angion Biomedica Corp. - Pipeline by Top 10 Route of Administration, 2015 23
Angion Biomedica Corp. - Pipeline by Top 10 Molecule Type, 2015 24
Angion Biomedica Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, H2 2016

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, ...

Hypertriglyceridemia - Pipeline Review, H2 2016

Hypertriglyceridemia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Hypertriglyceridemia - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides ...

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.